Superworth

RenovoRx EPS RNXT

Diluted earnings per share by quarter and over the last twelve months, from 2020.

Last 12 months, to Jun 30, 2026
n/m
a quarter missing
Latest quarter, Q2 FY26
−$0.06
Fiscal year 2023
−$1.01

RenovoRx's twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q2 FY26, it was −$0.06.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2023−$1.01n/a
FY2022n/an/a
FY2021n/an/a
FY2020n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.06n/an/a
Q1 FY26−$0.09n/an/a
Q3 FY25−$0.08n/an/a
Q2 FY25−$0.08n/an/a
Q1 FY25−$0.08n/an/a
Q3 FY24−$0.10n/a−$0.57
Q2 FY24−$0.10n/a−$0.60
Q1 FY24−$0.07n/a−$0.72
Q4 FY23−$0.30n/a−$1.01
Q3 FY23−$0.13n/a−$0.95
Q2 FY23−$0.22n/a−$1.06
Q1 FY23−$0.36n/a−$1.13

Against its peers

Companies in Medical - Instruments & Supplies nearest RenovoRx's size, closest first, today.

CompanyEPS, 12 monthsGrowth
RNXTRenovoRxn/m
APTAlpha Pro Tech$0.41+24% a year
NEPHNephros$0.16+33% a year
KEQUKewaunee Scientific$2.76−33% a year
PDEXPro DEX$4.11+52% a year
UTMDUtah Medical Products$3.28−12% a year
INFUInfuSystem$0.41+78% a year
EMBCEmbecta$1.47+3% a year
TCMDTactile Systems Technology$1.08+74% a year
MDXGMimedx$0.04−81% a year
Peer median$1.08

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on RenovoRx

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.